Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
2001 · PubMed · 549 citations
R
Roberto Bianco
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
497
Papers
12.2K
Citations
58
h-index
153
i10-index
Roberto Bianco is an academic researcher from Federico II University Hospital. The author has contributed to research in topics: Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research & Lung Cancer Treatments and Mutations. The author has an h-index of 58, co-authored 423 publications.
ORCID: 0000-0003-3311-260XPapers by this author
worksMechanisms of lapatinib resistance in HER2-driven breast cancer
2015 · Cancer Treatment Reviews · 160 citations
https://doi.org/10.1016/j.ctrv.2015.08.001
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
2008 · British Journal of Cancer · 134 citations
https://doi.org/10.1038/sj.bjc.6604269
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
2017 · British Journal of Cancer · 95 citations
https://doi.org/10.1038/bjc.2017.116
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
2014 · British Journal of Cancer · 86 citations
https://doi.org/10.1038/bjc.2014.241
RETRACTED ARTICLE: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
2014 · Breast Cancer Research · 66 citations
https://doi.org/10.1186/bcr3650
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat